What is Amphastar Pharmaceuticals, Inc.'s (AMPH) StockRank?

MoatMap's StockRank for Amphastar Pharmaceuticals, Inc. (AMPH) is 75/100, with a Buy signal. This is a composite score combining Quality (61), Value (78), and Momentum (29) factor ranks across MoatMap's 20,000+ stock universe.

Does Amphastar Pharmaceuticals, Inc. have an economic moat?

Amphastar Pharmaceuticals, Inc. (AMPH) has a Quality factor score of 61/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Amphastar Pharmaceuticals, Inc. a buy, hold, or sell?

MoatMap's current signal for Amphastar Pharmaceuticals, Inc. (AMPH) is Buy, based on a StockRank of 75/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Amphastar Pharmaceuticals, Inc. in?

Amphastar Pharmaceuticals, Inc. (AMPH) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AMPH

BUY

Amphastar Pharmaceuticals, Inc. · Healthcare · United States · $825M · Avg Vol: $10M/d

StockRank

Get insider-trade alerts

P/E (TTM)

11.9x

ROE

10.4%

D/E

0.9x

Dividend %

—

COMPANY DESCRIPTION

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets injectable, intranasal, and inhalation products, focusing on complex generics and proprietary drugs. The company's competitive advantage lies in its expertise with difficult-to-manufacture sterile products and a robust pipeline of both generic and branded pharmaceuticals. It leverages a vertically integrated structure to control critical raw material supply and manufacturing processes.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	499.0M	644.4M	732.0M	719.9M	13.0%	720.5M	746.4M	779.4M	4.0%
EPS	1.88	2.85	3.29	2.10	3.8%	1.65	1.68	1.94	-3.9%
Shares	48.1M	48.1M	47.6M	45.6M	-5.1%	44.1M	—	—	—
Debt	102.6M	623.6M	650.5M	656.0M	85.6%	686.4M	—	—	—
Equity	528.7M	639.4M	732.3M	788.8M	14.3%	—	—	—	—
Op CF	89.2M	183.5M	213.4M	156.1M	20.5%	168.9M	—	—	—
Inv CF	-32.8M	-649.1M	-124.9M	-70.3M	—	—	—	—	—
Fin CF	-26.4M	454.1M	-81.0M	-67.4M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-7.0%

SMA 50SMA 200

$18.87

RSI (14)

42.6

52W High

$31.26

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

10.1%74.6

ROE

10.4%73.3

GP/Assets

20.9%49.7

Op. Margin

8.0%62.3

FCF/Assets

6.3%75.1

Piotroski

668.2

Int. Cover

5.9x53.5

D/E Ratio

0.89x16.7

Current Ratio

3.85x63.4

Value

P/E (TTM)

11.9x84.5

EV/EBITDA

6.4x86.4

P/FCF

8.0x86.2

P/B

1.1x80.9

P/S

1.2x80.3

Div Yield

—N/A

Momentum

52W High %

60%39.5

RS 6M

-36%28.2

SMA 50/200

0.83x24.7

EPS Rev 4W

-4.5%8.9

EPS Rev 12W

-13.4%11.2

EPS Improve

+82%67.9

Q Growth

-75%4.0

FUNDAMENTALS

Market Cap

$825M

P/E (Forward)

6.5x

Gross Margin

47.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMPH are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AMPH	Amphastar Pharmaceuticals, Inc.(you)	$825M	75	BUY
PAHC	Phibro Animal Health Corporation	$1.4B	73	BUY
ETON	Eton Pharmaceuticals, Inc.	$1.2B	62	HOLD
EBS	Emergent BioSolutions Inc.	$375M	81	STRONG BUY
PCRX	Pacira BioSciences, Inc.	$1.0B	93	STRONG BUY
COLL	Collegium Pharmaceutical, Inc.	$1.1B	95	STRONG BUY
XERS	Xeris Biopharma Holdings, Inc.	$1.4B	59	HOLD
PBH	Prestige Consumer Healthcare Inc.	$2.4B	81	STRONG BUY
SIGA	SIGA Technologies, Inc.	$223M	76	BUY
TRLV	Trulieve Cannabis Corp.	$1.6B	89	STRONG BUY

Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.7%